Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women

Alexis D. Leal, Carrie A Thompson, Alice H. Wang, Robert A. Vierkant, Thomas Matthew Habermann, Julie A. Ross, Ruben A. Mesa, Beth A. Virnig, James R Cerhan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Hormonal and reproductive history has been associated with risk of some hematologic malignancies, but their role in myeloproliferative neoplasms (MPN) is largely unknown. Methods: Using a population-based cohort study, we evaluated the association of these factors with risk of MPN overall, and for essential thrombocythemia (ET) and polycythemia vera (PV) specifically. Incident MPN cases from 1993 to 2004 were identified via linkage to Medicare. RR and 95% confidence intervals (CI) were estimated utilizing Cox proportional hazard regression. Results: After >250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV). Ever use of hormone therapy (HT) was associated with an increased risk of ET (RR = 1.63; 95% CI, 1.19-2.23) but a decreased risk of PV (RR = 0.58; 95% CI, 0.34-0.98). There were no statistically significant associations of oral contraceptives or reproductive factors with MPN risk overall, or by MPN subtype. Bilateral oophorectomy was associated with increased risk of ET (RR = 1.58; 95% CI, 1.11-2.25) and decreased risk of PV (RR = 0.32; 95% CI, 0.12-0.88). There was no association of ovulatory years with ET risk; however, there was increased risk of PV (RR = 1.68 for >36.8 compared with ≤27.6 years; P trend = 0.045). Adjustment for potential confounding factors did not alter these associations. Conclusions: HT use and bilateral oophorectomy had opposite associations for ET and PV. Except for ovulatory years and PV risk, reproductive history did not appear to play a role in the etiology of MPN. Impact: This study suggests different mechanistic impacts of estrogen, and perhaps distinct etiologies, for the two major MPN subtypes.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Polycythemia Vera
Essential Thrombocythemia
Neoplasms
Confidence Intervals
Reproductive History
Ovariectomy
Hormones
Hematologic Neoplasms
Oral Contraceptives
Medicare
Estrogens
Cohort Studies
Therapeutics
Population

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women. / Leal, Alexis D.; Thompson, Carrie A; Wang, Alice H.; Vierkant, Robert A.; Habermann, Thomas Matthew; Ross, Julie A.; Mesa, Ruben A.; Virnig, Beth A.; Cerhan, James R.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 25, No. 1, 01.01.2016, p. 151-157.

Research output: Contribution to journalArticle

Leal, Alexis D. ; Thompson, Carrie A ; Wang, Alice H. ; Vierkant, Robert A. ; Habermann, Thomas Matthew ; Ross, Julie A. ; Mesa, Ruben A. ; Virnig, Beth A. ; Cerhan, James R. / Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women. In: Cancer Epidemiology Biomarkers and Prevention. 2016 ; Vol. 25, No. 1. pp. 151-157.
@article{ef66c2ca003c42dd925b00aa6061ecd7,
title = "Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women",
abstract = "Background: Hormonal and reproductive history has been associated with risk of some hematologic malignancies, but their role in myeloproliferative neoplasms (MPN) is largely unknown. Methods: Using a population-based cohort study, we evaluated the association of these factors with risk of MPN overall, and for essential thrombocythemia (ET) and polycythemia vera (PV) specifically. Incident MPN cases from 1993 to 2004 were identified via linkage to Medicare. RR and 95{\%} confidence intervals (CI) were estimated utilizing Cox proportional hazard regression. Results: After >250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV). Ever use of hormone therapy (HT) was associated with an increased risk of ET (RR = 1.63; 95{\%} CI, 1.19-2.23) but a decreased risk of PV (RR = 0.58; 95{\%} CI, 0.34-0.98). There were no statistically significant associations of oral contraceptives or reproductive factors with MPN risk overall, or by MPN subtype. Bilateral oophorectomy was associated with increased risk of ET (RR = 1.58; 95{\%} CI, 1.11-2.25) and decreased risk of PV (RR = 0.32; 95{\%} CI, 0.12-0.88). There was no association of ovulatory years with ET risk; however, there was increased risk of PV (RR = 1.68 for >36.8 compared with ≤27.6 years; P trend = 0.045). Adjustment for potential confounding factors did not alter these associations. Conclusions: HT use and bilateral oophorectomy had opposite associations for ET and PV. Except for ovulatory years and PV risk, reproductive history did not appear to play a role in the etiology of MPN. Impact: This study suggests different mechanistic impacts of estrogen, and perhaps distinct etiologies, for the two major MPN subtypes.",
author = "Leal, {Alexis D.} and Thompson, {Carrie A} and Wang, {Alice H.} and Vierkant, {Robert A.} and Habermann, {Thomas Matthew} and Ross, {Julie A.} and Mesa, {Ruben A.} and Virnig, {Beth A.} and Cerhan, {James R}",
year = "2016",
month = "1",
day = "1",
doi = "10.1158/1055-9965.EPI-15-0613",
language = "English (US)",
volume = "25",
pages = "151--157",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women

AU - Leal, Alexis D.

AU - Thompson, Carrie A

AU - Wang, Alice H.

AU - Vierkant, Robert A.

AU - Habermann, Thomas Matthew

AU - Ross, Julie A.

AU - Mesa, Ruben A.

AU - Virnig, Beth A.

AU - Cerhan, James R

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: Hormonal and reproductive history has been associated with risk of some hematologic malignancies, but their role in myeloproliferative neoplasms (MPN) is largely unknown. Methods: Using a population-based cohort study, we evaluated the association of these factors with risk of MPN overall, and for essential thrombocythemia (ET) and polycythemia vera (PV) specifically. Incident MPN cases from 1993 to 2004 were identified via linkage to Medicare. RR and 95% confidence intervals (CI) were estimated utilizing Cox proportional hazard regression. Results: After >250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV). Ever use of hormone therapy (HT) was associated with an increased risk of ET (RR = 1.63; 95% CI, 1.19-2.23) but a decreased risk of PV (RR = 0.58; 95% CI, 0.34-0.98). There were no statistically significant associations of oral contraceptives or reproductive factors with MPN risk overall, or by MPN subtype. Bilateral oophorectomy was associated with increased risk of ET (RR = 1.58; 95% CI, 1.11-2.25) and decreased risk of PV (RR = 0.32; 95% CI, 0.12-0.88). There was no association of ovulatory years with ET risk; however, there was increased risk of PV (RR = 1.68 for >36.8 compared with ≤27.6 years; P trend = 0.045). Adjustment for potential confounding factors did not alter these associations. Conclusions: HT use and bilateral oophorectomy had opposite associations for ET and PV. Except for ovulatory years and PV risk, reproductive history did not appear to play a role in the etiology of MPN. Impact: This study suggests different mechanistic impacts of estrogen, and perhaps distinct etiologies, for the two major MPN subtypes.

AB - Background: Hormonal and reproductive history has been associated with risk of some hematologic malignancies, but their role in myeloproliferative neoplasms (MPN) is largely unknown. Methods: Using a population-based cohort study, we evaluated the association of these factors with risk of MPN overall, and for essential thrombocythemia (ET) and polycythemia vera (PV) specifically. Incident MPN cases from 1993 to 2004 were identified via linkage to Medicare. RR and 95% confidence intervals (CI) were estimated utilizing Cox proportional hazard regression. Results: After >250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV). Ever use of hormone therapy (HT) was associated with an increased risk of ET (RR = 1.63; 95% CI, 1.19-2.23) but a decreased risk of PV (RR = 0.58; 95% CI, 0.34-0.98). There were no statistically significant associations of oral contraceptives or reproductive factors with MPN risk overall, or by MPN subtype. Bilateral oophorectomy was associated with increased risk of ET (RR = 1.58; 95% CI, 1.11-2.25) and decreased risk of PV (RR = 0.32; 95% CI, 0.12-0.88). There was no association of ovulatory years with ET risk; however, there was increased risk of PV (RR = 1.68 for >36.8 compared with ≤27.6 years; P trend = 0.045). Adjustment for potential confounding factors did not alter these associations. Conclusions: HT use and bilateral oophorectomy had opposite associations for ET and PV. Except for ovulatory years and PV risk, reproductive history did not appear to play a role in the etiology of MPN. Impact: This study suggests different mechanistic impacts of estrogen, and perhaps distinct etiologies, for the two major MPN subtypes.

UR - http://www.scopus.com/inward/record.url?scp=84955310797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955310797&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-15-0613

DO - 10.1158/1055-9965.EPI-15-0613

M3 - Article

VL - 25

SP - 151

EP - 157

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 1

ER -